Literature DB >> 1349888

Pharmacological analysis of positive chronotropic and inotropic responses to etilefrine in isolated dog heart preparations.

Y Karasawa1, Y Furukawa, M Murakami, L M Ren, S Takayama, S Chiba.   

Abstract

Positive chronotropic and inotropic responses to etilefrine (alpha-[(ethylamino)methyl]-m-hydroxybenzyl alcohol), an orally active cardiovascular agent, were investigated in isolated dog right atrial and left ventricular preparations. Intravenous administration of etilefrine to a support dog increased heart rate and mean systemic blood pressure, and increased sinus rate and atrial contractile force in the isolated right atrium perfused with blood from the support dog. Etilefrine injected intra-arterially to isolated atria and ventricles induced dose-dependent positive chronotropic and inotropic effects. Etilefrine was about 100 times less potent than isoproterenol. The effects of etilefrine in isolated atria were significantly inhibited by treatment with atenolol, but were not significantly inhibited by ICI 118,551. The effects of etilefrine were partially inhibited by imipramine. These results indicate that etilefrine is a highly selective beta-1 adrenoceptor agonist and suggest a moderate catecholamine-releasing activity by tyramine-like action in the blood-perfused dog heart.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349888     DOI: 10.1007/bf01745864

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  31 in total

1.  The cardiovascular effects of etilefrine.

Authors:  A J Coleman; W P Leary; A C Asmal
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

2.  Comparison of beta adrenergic receptor subtypes in mammalian tissues.

Authors:  K P Minneman; A Hedberg; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1979-12       Impact factor: 4.030

3.  Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins.

Authors:  O Thulesius; J E Gjöres; E Berlin
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

4.  A comparison of the effects of noradrenaline, adrenaline and some phenylephrine derivatives on alpha-, beta- and beta- adrenergic receptors.

Authors:  J Offermeier; A C Dreyer
Journal:  S Afr Med J       Date:  1971-03-06

5.  An approach to the evaluation of sympathomimetic amines by measuring the decrease of ear temperature in rabbits and dogs.

Authors:  T Hiraoka; J Serizawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1974-02       Impact factor: 1.645

6.  Differentiation of cardiac and peripheral alpha- and beta-adrenergic responses to dobutamine, etilefrine and xylometazoline in dogs.

Authors:  R Walkenhorst; D Reinhardt; G Arnold
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

7.  The indirect sympathomimetic activity of etilefrine--a comparison with tyramine and ephedrine using [3H] noradrenaline.

Authors:  B R Frost; T N Halloran; D B Frewin; D C Gerke; J A Downey
Journal:  J Pharm Pharmacol       Date:  1978-10       Impact factor: 3.765

8.  Dihydroergotamine increases the bioavailability of orally administered etilefrine.

Authors:  J H Hengstmann; R Hengstmann; S Schwonzen; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Predominant sensitivity to tyramine in the isolated intermediate auricular artery of the dog.

Authors:  S Chiba; T Ito
Journal:  J Auton Pharmacol       Date:  1985-06

10.  Comparison of the beta-adrenoceptor affinity and selectivity of cetamolol, atenolol, betaxolol, and ICI-118,551.

Authors:  T J Rimele; D E Henry; F R Giesa; S K Buckley; G Geiger; R J Heaslip; D K Lee; D Grimes
Journal:  J Cardiovasc Pharmacol       Date:  1988-08       Impact factor: 3.105

View more
  1 in total

Review 1.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.